1 Article

Determining factors for pertussis vaccination policy: A study in 5 EU countries

Anabelle Wong 12,3*, Annick Opinel 1, Simon Jean-Baptiste Combes 4,5, Julie Toubiana 6,7,8 and Sylvain Brisse 6,7

- Institut Pasteur/Inserm/UVQS, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), 25 rue du Dr Roux, F- 75724 Paris Cedex 15, France.
- 8 ² EHESP, F-35000 Rennes, France.
- 9 ³ ScHARR, the University of Sheffield, 30 Regent Street, Sheffield S1 4DA, United Kingdom.
- 10 $\,^{_{4}}\,$ Univ Rennes, EHESP, CNRS, ARENES UMR 6051, F-35000 Rennes, France.
- 11 ⁵ French Collaborative Institute on Migration, 93322 Aubervilliers, France.
- Institut Pasteur, Unit Biodiversity and Epidemiology of Bacterial Pathogens, 25 rue du Dr Roux, F- 75724
 Paris Cedex 15, France.
- National Reference Center for Whooping cough and other Bordetelloses, Institut Pasteur, 25 rue du Dr
 Roux, F- 75724 Paris Cedex 15, France.

16 ⁸ Université de Paris, Department of General Paediatrics and Infectious Diseases, Necker-Enfants malades
 17 University Hospital, AP-HP, 135 rue de Sevres, 75015, Paris, France.

- 18 * Correspondence: anabelle.wong@eleve.ehesp.fr
- 19 Received: date pending; Accepted: date pending; Published: date pending

20 Abstract: Pertussis vaccination policy varies across Europe, not only in the type of vaccine - whole 21 cell (wP) vs. acellular (aP1/2/3/5) – but also in the schedule and recommendation for parents. This 22 study aims to investigate the determining factors for the type of vaccine, immunization schedule 23 and maternal immunization recommendation. From March to May 2019, experts in national health 24 agencies and major academic or research institutions from Denmark, France, Poland, Sweden and 25 the UK were invited to a semi-structured interview. Thematic analysis was performed on the 26 transcripts using a codebook formulated by 3 coders. Inter-coder agreement was assessed. Fifteen 27 expert interviews were conducted. The identified driving factors for pertussis vaccine policy were 28 classified into three domains: scientific factors, sociological factors, and pragmatic factors. The 29 determining factors for the type of vaccine were prescriber's preference, concern of adverse events 30 following immunization (AEFI), effectiveness, and consideration of other vaccine components in 31 combined vaccines. The determining factors for infant schedule were immunity response and the 32 potential to improve coverage and timeliness. The determining factors for maternal immunization 33 were infant mortality and public acceptability. To conclude, socio-political and pragmatic factors 34 were, besides scientific factors, important in determining the vaccine type, schedule of childhood 35 immunization and recommendations for parents.

36 Keywords: Bordetella pertussis; whooping cough; vaccination policy; national immunization
 37 program

38 39

40 1. Introduction

Whooping cough is an acute respiratory infection characterized by repeated, intense cough bouts that can last for 2 to 3 months [1]. In 1906, the pathogen causing whopping cough was found to be a Gram-negative bacterium, *Bordetella pertussis* (*B. pertussis*) [2]. It is highly contagious and spreads via droplets of the coughs or sneezes of an infected person [1]. Before vaccines became available, it was a major cause of infant mortality [3].

46 The earliest vaccines against pertussis were inactivated whole cell pertussis vaccines (wP) 47 developed in 1930s to 1950s; routine pertussis vaccination in children less than 12 months started in the late 1950s in Europe [4]. wP have been replaced by acellular pertussis vaccines (aP) in many
European countries since the 1990s [2,5]. aP do not contain the whole bacterium but only antigens; it
was suggested that aP have lower reactogenicity and are better accepted [3].

51 After more than half a century, whooping cough has yet to be eradicated and there are signs for 52 resurgence despite routine childhood immunization [3,6] with high coverage [5]. Some authors have 53 hypothesized that the resurgence is due to short-lived protection from aP compared to wP [6,7]. 54 Nevertheless, the waning of immunity from aP cannot explain all of the resurgence. For example, in 55 the Netherlands and in Denmark, the incidence of whooping cough began to surge before wP were 56 replaced by aP in the national immunization program [6,8]. Evidence from recent research supports 57 the adaptation of *B. pertussis* to vaccine-induced immunity through antigen evolution [7,9]. Most 58 notably, some strains of pertussis no longer produce pertactin (PRN) [3,4,5,10], a protein that enables 59 the bacteria to attach to the lining of human's airway [11] and which is one of the components used 60 in 3-component (aP3) and 5-component (aP5) vaccines [3,4,5,10,11]. The PRN-negative characteristic 61 appears to give *B. pertussis* an advantage in surviving in aP-vaccinated populations [5,11,12,13]. 62 However, other vaccine components continue to provide protection against *B. pertussis*. Currently, 63 there is no evidence that the PRN-negative strains cause more severe pertussis infection [14,15] and 64 one study showed that the proportion of apnea was lower among PRN-negative cases [12].

Pertussis vaccination is an indispensable strategy towards disease control and prevention. However, the dynamics of vaccination policy are complex. Understanding determinants of vaccine policy is a step forward in the optimization of national immunization efforts. The scope of this study focuses on the relationships of the content and context of pertussis vaccination in Europe. The content is defined as i) the type of vaccine, ii) national immunization schedule and iii) recommendations for pregnant women in pertussis vaccination; while the context comprises determining factors for the policy.

72 The type and schedule used in the national immunization programs in Europe have evolved 73 since the introduction of pertussis vaccine in 1950s (Appendix A) [3,4,6,16-50], leading to 74 considerable heterogeneity in pertussis vaccination policies across Europe. Currently, the most 75 common type of vaccine used in Europe is multi-component aP (aP2/3/5). Two-component aP (aP2) 76 contains two antigens: pertussis toxoid (PT) and filamentous hemagglutinin (FHA); aP3 contains the 77 additional antigen PRN; and aP5 contains PT, FHA, PRN, and fimbriae (Fim) types 2 and 3 [4]. While 78 France allows the use of all three types of multicomponent aP, Denmark had until recently relied 79 exclusively on a 1-component aP vaccine (aP1) that contains only PT [51]; whereas Poland remains 80 the only country in Europe that uses wP in the national childhood immunization scheme [46]. Given 81 the existing evidence on efficacy and safety of pertussis vaccines and the similar profiles of 82 B. pertussis strains circulating in Europe [3,4,5,9,10], such diverse vaccination policies across Europe 83 lead to the hypothesis that pertussis immunization strategy is not solely determined by scientific 84 factors but may also be influenced by socio-historical factors as well as pragmatic reasons.

Two main patterns of the first series of pertussis immunization schedules for children are currently used in Europe [16]: i) the accelerated schedule: 2/3/4 or 2/4/6 month with or without the 4th dose before the age of 2 years; and ii) the long schedule: 2/4/11 or 3/5/12 month.


88 The accelerated schedule consists of 3 doses of vaccines in the first 6 months of life whereas the 89 3 doses of vaccines in the long schedule are given in a span of 11 to 12 months [52]. The 90 immunization schedules vary among countries using the same type of vaccine. The initiation of 91 infant immunization can be at 2 or 3 months. Studies conducted in the 1990s did not offer conclusive 92 evidence. Some studies suggested higher serological response using the long schedule [53,54]; 93 however, no good serological correlate of protection has been identified [52]. Systematic review also 94 found no good data for the comparison of different schedules in terms of effectiveness [52]. Besides, 95 the evidence of the age of infant immunization initiation having an impact on immunogenicity or 96 effectiveness is limited [52]. Under such circumstances, the observation of the variation of infant 97 immunization schedule further supports the hypothesis that pertussis immunization strategy is 98 influenced by factors other than existing evidence in efficacy or effectiveness. This study aimed to 99 investigate the factors that determined the pertussis immunization strategy in European countries 100 that have distinctive vaccination policies.

101 2. Materials and Methods

102 2.1. Selesction of countries

103 Official reports from national health agencies and scientific and medical journals were reviewed 104 [3,4,6,16-50] to provide information on the current pertussis vaccination policy in 11 EU countries 105 that have participated in any one of the 4 EuPertStrain studies (Appendix A). The 106 EuPertStrain studies were established within the European network in 2011, aiming to monitor 107 changes in the European *B. pertussis* populations in order to optimize vaccine strategies [3,4,5,10]. 108 Figure 1 shows the type of vaccine used and the first series schedule of childhood immunization in 109 11 EU countries. Five of these countries were then selected for a qualitative study based on the type 110 of vaccine being used, different recommendations for parents, and different schedules for childhood 111 immunization.

- 112
- 113



114 115

116

117

Figure 1. The type of vaccine used, the first series immunization schedule and recommendations for parents in 11 EU countries (*NL started recommendations for maternal vaccination during the study).

118 Denmark and Poland were selected due to the unique immunization agents used. The UK was 119 selected as it is the first country in Europe to have implemented mass vaccination for pregnant 120 women [1]. France was selected due to its recommendation for the cocooning strategy – a strategy 121 that aims to fill the vulnerable gap for pertussis infection in children between 0 to 6 weeks by 122 vaccinating the individuals in close contact with the newborn [16,33]. Owing to a unique history of 123 using aP1 exclusively in Gothenburg from 1996 to 1999 [50] and its "vaccine vacuum" from 1979 to 124 1996, Sweden was also included in this study to contribute information about vaccine policy 125 evolution. In terms of childhood immunization schedule, Poland and the UK adopted the 126 accelerated schedule while Denmark, France and Sweden followed the long schedule.

127 2.2. Methods for interviews

Semi-structured interviews with experts in selected countries were conducted to gain understanding on the factors determining pertussis vaccination policy. Key informants were selected due to their role, experience and knowledge in the field of childhood immunization [55]. The purpose of a semi-structured interview was to encourage expert participants to share their observation and understanding about the phenomenon in vaccination policy making. Experts were 133 identified in the process of literature review and via searching the official websites of major 134 academic and national institutions in selected countries. Individuals who fulfilled the inclusion 135 criteria (Table 1) were recruited. Further informants were recruited by snowball sampling because 136 sampling in this study was purposive and it aimed at maximum variation of information [56]. The 137 sampling frame aimed to recruit experts from different professional backgrounds within the same 138 country and to obtain representation from experts involved in policy decisions as well as those who 139 were not involved in the national decision process. Interviews were conducted in person or via 140 Skype or phone when a face-to-face meeting could not be arranged. The interviews followed a set of 141 open-ended questions in the topic guide developed based on Boyce and Neale's template [57]. The 142 interviews were audio-recorded and transcripts were produced based on the audio-file. The 143 transcripts were sent back to participants for checking and signing as an endorsement of accuracy. 144 Upon receiving the endorsed transcript, the audio-recording would be deleted. In cases where the 145 expert had not sent back an endorsed transcript, draft transcript was used for analysis while 146 pending future transcript endorsement to trigger the deletion of the audio-file. The transcripts were 147 anonymized by the allocation of a transcript ID.

148

Table 1. Inclusion and exclusion criteria for participant recruitment.

Inclusion Criteria
1) Have work experience of 3 years or above in the field related to vaccination policy or
pertussis research in the country;
2) Have professional knowledge on pertussis vaccine or vaccination policy in the country;
3) Are able to communicate effectively in English;
4) Are willing to participate and have given informed consent.
Exclusion Criteria
1) Vaccine manufacturers and their employees;
2) Withdrawn consent during or after interview.

149

150 Demographic information and characteristics of participants were summarized by descriptive 151 statistics. Thematic content analysis was performed on the anonymized transcripts using a codebook 152 formulated based on grounded theory. It means that the codebook did not rely on any pre-existing 153 theory but consisted of recurrent concepts emerged from the interviews; therefore the codebook was 154 considered grounded in data [58]. The process of coding was guided by the 3-stage approach 155 proposed by Campbell and colleagues [59]. In the first stage, a codebook by one knowledgeable 156 coder was developed based on all transcripts. A knowledgeable coder was defined as a coder who 157 had insights on all transcripts. This codebook was used by three independent analysts to code two 158 pilot transcripts: one from the interview with a health scientist and the other with a social scientist. 159 As the vocabulary used and the concepts brought up by experts with these professional 160 backgrounds can vary significantly, the code used would vary accordingly. The second stage 161 involved adjudicating coding disagreement through discussion [59]. In this stage, the codebook was 162 refined as ambiguous and overlapping codes were deleted and necessary new codes created based 163 on the consensus of the three coders. Inter-coder agreement was assessed after pilot coding. In the 164 third stage, the codebook was deployed to the full set of anonymized transcripts by one 165 knowledgeable coder once inter-coder agreement was established. All codes were arranged into 166 categories and plotted for conceptualization. All transcripts were processed in R version 3.5.1 and 167 RStudio version 1.1.456 using the package "RQDA".

168 Inter-coder agreement was assessed using Krippendorff's alpha, which is a generalized version 169 of inter-rater agreeability statistic that can be applicable in nominal data and in situations where 170 there are more than 2 observers [60]. The interpretation of Krippendorff's alpha was based on the 171 guideline drawn up by Landis and Koch [61].

173 2.3. Ethicalapproval

The study has obtained approval from the Ethical Committee (EC) of the University of Sheffield, UK. Regarding the nature and study design of this study, EC approval or notification was not required in Denmark, France, Poland and Sweden. Further to EC requirements in selected countries, this study observed and complied with the EU General Data Protection Regulation (GDPR) as well as the country-specific regulations if the scope of such regulation applied.

179 3. Results

From March to May 2019, 34 experts were contacted, and 15 interviews had been conducted by
the end of May, 2019. The 15 experts had experience ranging from 5 to 35 years and the median year
of experience was 18 years. Table 2 shows more demographic information including country,
professional background and whether the expert was involved in the vaccination policy process.

Among the 19 non-responders, 6 declined for not having sufficient knowledge or experience in the topic, not being actively involved in related duties anymore, or being too occupied with other priorities. The characteristics of the non-responders were analyzed. Non-responders more often came from Sweden and the UK (n=15); and were more often experts in the field of social and political science (n=10).

189 190

Table 2	Demographic	characteristics	of participants.

Demographic characteristics		Ν
Total		15
Country	Denmark	3
	France	4
	Poland	2
	Sweden	3
	UK	3
Professional background	Social & Political Science	4
	Epidemiology & Medicine	7
	Microbiology & Immunology	4
Involvement in Policy Process	Yes	9
-	No	6

192

193 3.1. Inter-coder agreement

Inter-coder agreement among the three coders was assessed using Krippendorff's alpha (Table
3). Disagreements among coders came from the inconsistency within one coder as well as the
inter-coder differences in the interpretation and application of the coding guidelines [60].

Table 3. Inter-coder agreement in pilot coding using two transcripts.

Transcript Profile	Coding Unit	Krippendorff's alpha ^[60]	Interpretation ^[61]
Epidemiology & Medicine	75	0.621	Substantial
Social & Political Science	57	0.598	Moderate
Total	132	0.616	Substantial

¹⁹⁸

199 The Krippendorff's alpha based on the health scientist's transcript was slightly higher than that 200 based on the social scientist's transcript. The small difference between the Krippendorff's alphas of 201 the 3 coders based on the 2 transcripts also suggested that the levels of agreement among coders 202 were similar when interpreting discussions offered by experts of different backgrounds. The overall inter-coder agreement by Krippendorff's alpha was 0.616, indicating substantial agreement
 according to Landis and Kock's interpretation framework (Table 2) [61].

205 3.2. Determining factors of pertussis vaccination policy

The determining factors referred to the reasons for the change in policy or the ground for policies remaining unchanged. These factors were identified from the interviews and triangulated by experts from the same country.

The codes derived from the transcripts were categorized into three domains: scientific factors, sociological factors, and pragmatic factors. Figure 2 shows the determining factors for pertussis vaccination policy under different domains.

212

Scientific Factors	 Cases /epidemics / outbreaks AEFI / safety profile Surveillance / data availability Immunity response Duration of protection 	 Infant death & non-fatal outcomes Transmission in population Effectiveness Protect mothers/infants & herd immunity Technical production process
Sociological Factors	 Public acceptance & uptake Social contact structure Attitude & behaviour of HCP Attitude & behaviour of public 	 Awareness & perception of pertussis Historical events / vaccine scares Trust in HCP & authorities
Pragmatic Factors	 Marketing authorisation Cost-effectiveness Affordability & cost / price 	 Accessibility & timeliness Production / supply Consumption / demand

213

214Figure 2. Determining factors of pertussis vaccination policy: (a) scientific factors; (b) sociological215factors; (c) pragmatic factors.

216 3.3.1. Type of vaccine

Regarding the change from wP to aP, a range of reasons were mentioned. While most experts (n=10) believed the concern of adverse events following immunization (AEFI) was causing the change, some experts who were involved in the decision making process pointed out other more proximal reasons (n=5) for the change in the type of vaccine being used in the national immunization program.

222 Experts in France stated that the prescriber's preference contributed to the change. According to 223 the experts, the country recommended using wP in the first series of childhood immunization until 224 2004; however, since the introduction of aP booster for the age group of 11 to 14 years in 1998 in 225 France and subsequent availability of aP, many general practitioners and pediatricians prescribed aP 226 for the prime vaccination of the infants. According to the experts, due to increasing consumption of 227 aP and decreasing demand of wP, manufacturers decided to produce only aP instead of maintaining 228 two production lines. That ultimately caused the change in recommendation from using wP to aP in 229 the immunization for all age groups.

Experts in Sweden pointed out the fact that despite a high coverage of wP before the change, pertussis cases in infants were not reduced. Therefore, the wP vaccine was deemed ineffective and the national pertussis immunization program was suspended from 1979 to 1996. It was resumed when aP became available and after its effectiveness had been proven. In the UK, wP was recommended for the infant immunization program until 2004. According to the experts, coverage of the vaccine program plummeted due to concern about AEFI in the 1970s and 1980s, but confidence was restored in wP given abundant efforts in independent review about the safety of the wP vaccine, leading to increased and sustained high coverage. The change from wP to aP was actually driven by the need of an inactivated polio vaccine, which was available in a multivalent vaccine that contained an aP component.

Poland was the only country in the EU that is still using wP. According to the experts in Poland,
the wP used had desirable effectiveness and did not induce concern about AEFI. As the vaccine was
produced in the country, the supply was stable. It was also a more affordable option.

243 Regarding the switch from aP1 to aP2/3/5, experts from Sweden shared that it was the tender 244 process that drove the change. As aP1 vaccines were only produced in Denmark, since the 245 manufacturer did not participate in the tender process, it was not available for selection in the 246 Swedish national immunizations program. Before this study commenced, Denmark was the only 247 country that had been using aP1 [51] since the change from wP to aP in 1997. However, experts in 248 Denmark reported in the interview during this study that the country has just changed from using 249 aP1 to aP2/3/5 and the reason was also due to aP1 manufacturer stopping its participation in the 250 tender process.

251 3.3.2. Immunization schedule

Concerning the accelerated and long schedule for infant immunization, most experts regarded it to be a decision based on clinical data from trials of the vaccines and the authorized posology recommended by manufacturers. However, since both schedules were proven to be effective and the recommendation by the World Health Organization (WHO) also allows certain flexibility [62], countries made their decisions based on various factors and priorities.

Experts from Denmark and Sweden, where long schedule (3/5/12 month) was used, shared that such decision was based on data from clinical trials within the country and that such schedule allowed desirable immunogenicity and effectiveness.

260 "That was in the 80s, we looked at the pertussis trial and we found that the immune response is the best if
261 you give the vaccine at 2-month intervals instead of 1-month intervals. And it's better to start at the age of 3
262 month compared to 2 month..." (Sweden expert)

France adopted the accelerated schedule in 1995 but has changed to a long schedule in 2013. However, in 2013, France used a long schedule that consisted of three doses at 2, 4, 11 month instead of the 3/5/12 month standard long schedule. According to the experts, an earlier initiation of immunization was due to the concern of cases in very young infants – those who might be infected by pertussis before receiving the first dose of vaccine at the age of 3 month according to the standard long schedule.

269 "And in France, we decided to adopt such a schedule but we did not want to start at 3 month because we
270 knew that if you start one month later, you will have more pertussis cases. So we chose to start at 2 months..."
271 (France expert)

The accelerated schedule (2/3/4 month) was used in the UK. Experts shared that when the 3rd dose of primary pertussis vaccination was closer to an older infant age around 11 month; there was a drop-off in uptake of that 3rd dose. By adopting the accelerated schedule, coverage was increased and timeliness of the three doses of first series of vaccine was improved.

276 "The advantage of having an accelerated course is that you're not only offering protection at an earliest
277 infant age but also we've found that you're more likely to achieve higher uptake, when you're offering it at an
278 earlier age." (UK expert)

279 3.3.3. Maternal vaccination

A consensus was observed among experts from different countries that the main reason for recommending vaccination during pregnancy was an epidemic or increased infant death.

282 "...we have no, well, very few infant deaths. And that is the major marker for introducing the vaccination
283 in pregnancy, of course. We had an epidemic in 2016. And that's prompted, the Health Authority to think about

renewing the vaccination strategies. And vaccination in pregnancy was one of them although we haven't
 implemented it." (Denmark expert)

286 "So now it has changed in favor of maternal vaccination. Pertussis is not a big problem for the moment,
287 but in case there will be an increase of infants infected with pertussis, I think there will be a change in the
288 program towards this recommendation." (Sweden expert)

"We experienced a very significant increase in overall rate of disease across the entire population, but
 particularly in those very young babies. And we had an increase in pertussis deaths, we had 14 deaths from
 pertussis in 2012. So the introduction of the maternal program was very much introduced and prompted by the
 increased rate of disease. We've done it as an emergency program..." (UK expert)

In countries where infant deaths remained low, such as Denmark and Sweden, experts suggested that maternal vaccination would enter the policy discussion when pertussis-related infant deaths increased. In the UK, where a major epidemic with increased infant deaths occurred in 2012, such strategy was adopted as a response to the emergency.

However, there were also recurrent concerns about such policy. These concerns included acceptability of maternal immunization by health care professional (HCP) and by the general public and the limited data on immunity blunting, which is a phenomenon where trans-placentally acquired antibody lowers the immune response to infant immunization [19].

301 "Well, it's typical that one reason why we didn't jump at that strategy is that we have the question mark of 302 what will be the acceptance rate of such a strategy." (France expert)

303 "...we have an investigation in the public health agency a couple of years ago. At that time, there was some
304 hesitancy. They were looking for more data. There's some kind of blunting or immune response in the children."
305 (Sweden expert)

306 3.3.4. Other important discourse: policy implementation

319

307 During the interviews, some experts (n=2) expressed that pertussis vaccination was not a 308 frequently debated topic in the country as vaccination debates focused on other vaccines, such as 309 HPV vaccines.

Some experts (n=3) offered a discussion on the paradigm of vaccination policy process. In Poland, there was recently a vote in parliament about abolishing mandatory vaccination, which was triggered by citizens' petition; and in France, there had been a citizen consultation before the country expanded mandatory vaccination in 2018 from 3 vaccines to 11 vaccines. Those events led countries to discuss themes related to public-professional and public-authority relationship. Some experts shared that they were concerned about how policy was made would have an impact on the perception, attitude or behavior of the general public regarding vaccination or towards HCP:

317 "And something that might fuel distrust towards the expert professionals, in Poland at least, is the 318 strength and unquestionability of the consensus already existing among professionals." (Poland expert)

The use of mandatory vaccination may lead some people to be more radical:

320 "....that doesn't mean they were against vaccines, it just means that they were against mandatory 321 vaccination... is it going to push part of the people who are hesitant towards a more radical stance, you know, 322 going to very private schools, where they look the other way and don't really check whether the children are 323 vaccinated? And the issue is whether it's going to create small pockets of severely under-vaccinated people..." 324 (France expert)

According to the some experts, mandatory vaccination may be seen as a way to restore public confidence in vaccines in France and as the consensus or approval of the authority and professionals in Poland. Other countries found voluntary vaccination based on national recommendation a better suiting strategy. Some experts also expressed doubts about the message or implication conveyed by vaccine mandates:

330 *"I can't see a reason for introducing a compulsory element to this because it's a program that's already*331 *very well delivered and very well received. So I can't see a role for mandating in our population at this time.*332 *And I doubt it would improve uptake, and it could be counterproductive." (UK expert)*

333 "...but if the results speak for themselves and the health authorities recommend something, people tend to
334 do that. And I believe, and I know I'm not alone in believing that, if we were to make mandatory vaccination, it

335 would actually spark this hesitancy, it would spark distrust. And I think it would be detrimental for our 336 program to do that." (Denmark expert)

337 4. Discussion


338 In this work we first reviewed the literature to define the extent of variation of vaccination 339 policies across EU countries. We then selected 5 countries with contrasted policies to conduct an 340 investigation of vaccination policy determinants. In the semi-structured interview, experts from 341 Denmark, France, Poland, Sweden and the UK were asked about their perception of the 342 determinants for changes in the type of *pertussis* vaccine (wP / aP1 / aP2,3,5) and schedule being used 343 in the national childhood immunization program, and the reasons for such changes, if any. Experts 344 were also asked why cocooning strategy or maternal vaccination might be important to the country, 345 if there was such recommendation in place.

All participating countries except Poland experienced the switch of wP to aP in national immunization against *pertussis*. Although it is widely believed that aP is better tolerated than wP [3], it was not the main reason for the switch in France, Sweden and the UK. Moreover, the wP in Poland did not trigger concern about AEFI. An explanation for these observations is that wP, of which the production process is not standardized, showed different efficacies and safety profiles in different countries, leading to heterogeneity in the discontinuation or continuation of wP in national immunizations program.

353 One of the recurrent messages brought up by experts was the inappropriate comparison 354 between wP and aP in literature and in nowadays' debates. Experts reminded researchers and policy 355 makers that wP and aP comparison would not be meaningful and can be misleading when the strain 356 of wP was not specified or characterized. The efficacy and safety profile of wP depended on the 357 specific strain and the production of the vaccine. Some countries used locally produced wP; 358 therefore the quality, efficacy and safety profile of the vaccines across countries would vary. Even 359 within the same country, wP still varied from year to year, and from batch to batch. This also 360 explained why the decision of using wP or aP and the reasons for the switch differed from country to 361 country. If the country had a wP with good effectiveness and desirable safety profile, wP tended to 362 remain in use for longer periods. As different wP have different safety profiles, it is therefore 363 important to be precise about the wP when the concern of AEFI is addressed.

Often mentioned was the "side effects" or "safety profile" of wP but the more important concept is the distinction between the actual AEFI that occurred and the concern about the AEFI. The former is a factual concept – frequency and severity of the AEFI that occurred; the latter is a concept about perceived risk and a measure of attitude.

368 Looking closer at the driving factors for the change from wP to aP in the selected countries, 369 there appeared to be an interdependent relationships among scientific factors, sociological factors 370 and pragmatic factors. This study leads us to propose a mechanism of influences among cases of 371 AEFI, the concern about AEFI and the behavioral adaptation (Figure 3). Hidden influence or 372 relationship, such as the influence from manufacturer on HCP and policy makers, or the influence 373 from media and social media on HCP and policy makers, can be present. The existing literature on 374 vaccination policy also highlighted that transparency of the decision process needs improving [63]. 375 Therefore, while deciphering the driving factors in vaccination policy, one must bear in mind the 376 potential hidden driving factors or the concealed relationship between factors.



378 379

Figure 3. Relationship between AEFI and the concern about AEFI among public and HCP.

The determination of the childhood immunization schedule against pertussis appeared to result from a balance of three essential factors: i) immunogenicity; ii) earliest immunization possible; and iii) highest uptake possible. These three independent but important factors justify the flexibility included in the WHO recommendations [62] and offer a basis for vaccine policy makers to weigh the above-mentioned factors according to the country-specific context.

385 Closely related to the determination of the childhood immunization schedule are the 386 recommendations for parents. Most experts agreed that maternal vaccination became a topic of 387 discussion when an epidemic or an increase in pertussis-related infant deaths was observed in the 388 country. Such finding is coherent with the policy evolution in the UK, as the UK government 389 introduced a temporary immunization program for pregnant women from October 2012 as a 390 response to the national outbreak declared in April 2012 [64]. Later in June 2014, the Joint Committee 391 on Vaccination and Immunisation (JCVI) advised the program to continue for another five years 392 before further evaluation [64]. Such evaluation shall offer an abundance of evidence that may 393 answer many questions about the longer term safety, efficacy and cost-effectiveness of the national 394 maternal immunization program.

395 A similar case was observed in an oversea Department of France: the increase in pertussis cases 396 among infants in Mayotte in 2017 has sparked the discussion that led to the implementation of local 397 maternal immunization as a response to the epidemic [65]. The outbreak in Mayotte was partly due 398 to insufficient coverage of childhood immunization program caused by the breakdown of health 399 care infrastructure [65]. Further, the Technical Commission of Vaccinations (Commission Technique 400 des Vaccinations, Haute Autorité de Santé) has affirmed that maternal vaccination is more efficient 401 and beneficial than the cocooning strategy in protecting infants too young to be vaccinated in the 402 context of major epidemics [66]. Hence, the situation in Mayotte might influence an evolution of 403 maternal vaccination recommendations even in mainland France.

404 As primary research, this study offered abundant data and will allow further analyses. Its 405 sampling frame aimed to obtain representation from all five selected countries. In each country, at 406 least two different professional backgrounds were included in order to maximize data variation and 407 to serve the purpose of triangulation. The median duration of experts' experience was 18 years, 408 indicating that the study sample has long duration of exposure in the field of interest and can be 409 considered as a credible source of information. The data collection relied on audio-recording, 410 together with the transcript endorsement process, which ensured the accuracy of data and thus 411 increased the internal validity of the study. Qualitative research is often attacked for being subjective 412 and biased [67], especially when there is ambiguity in the data or when certain codes belong to more 413 than one coding categories [68]. To increase rigorousness and external validity, this study 414 endeavored to establish a reliable codebook with an assessment of the inter-coder agreement of three 415 coders who had worked on the same set of transcripts [59,60]. Although the sample size was small 416 (n=15), no new code arose towards the last few interviews and a large amount of recurrent codes 417 were observed, suggesting saturation of knowledge, which was the purpose of this qualitative 418 research using the method of interview [69].

419 There were a few limitations in this study. Firstly, the study sample included more scientists 420 from the natural and health disciplines than social and political ones, which caused the data to be 421 more science-centric. The reason for such sample composition was driven by the reality that more 422 experts from the field of natural science and health science responded to the study invitation than 423 experts from the field of social and political science. This could be due to no or very few sociologists 424 and political scientists working on pertussis vaccination specifically, and some may not feel 425 comfortable participating in a study on pertussis vaccination policy. Secondly, the set duration of 30 426 minutes was a limiting time frame for an interview, so some participants did not cover all topics on 427 the interview topic guide. Thirdly, as discussed above, hidden external influence such as that from 428 the pharmaceutical industry cannot be assessed. This may or may not have affected the neutrality of 429 experts' opinions [70]. Since participants did not declare conflict of interests, it was not possible to 430 estimate the impact of such influence on this study. As with many studies using the method of 431 qualitative interview, unitization of transcripts was a limitation in this study [59,60]. In the content 432 analysis, coding units were "units of meaning" instead of demarcated parts of text. Such unitization, 433 despite being more appropriate in this exploratory research study using complex interview data 434 [59], tends to result in lower inter-coder agreement [59,60]. Lastly, the five countries had different 435 surveillance systems and strategies in place, which may influence the experts' perception of 436 determining factors for pertussis vaccination policy.

437 5. Conclusions

438 By disputing the oversimplified version of safety- and efficacy-driven vaccine policy, the 439 findings of this study contribute to a better understanding of the determining factors that drive 440 pertussis vaccination policy. The choice of the immunization agent was influenced by prescriber's 441 preference, concern of adverse events following immunization (AEFI), effectiveness, and 442 consideration of other vaccine components in combined vaccines. The schedule of childhood 443 immunization was determined by immunity response and the potential to improve coverage and 444 timeliness. The recommendations on maternal immunization hinges on infant mortality contributed 445 by pertussis in the country as well as acceptability of such strategy by HCP and the general public.

To better guide pertussis vaccination policy, future researchers should pay attention to should pay attention to the impact of changes in vaccine policies on pertussis epidemiology within a country and dynamics of transmission in Europe and worldwide. More efforts and attention should be given to sociological research on pertussis vaccination strategies, especially on the attitude and behavior of HCP and the public. Including sociological expertise in the decision making and increasing the transparency of decision process may also help build public's trust in the vaccine policy decision process.

453 Author Contributions:

454 Conceptualization, Anabelle Wong, Annick Opinel, Julie Toubiana and Sylvain Brisse; methodology, Anabelle 455 Wong and Annick Opinel; software, Anabelle Wong and Simon Jean-Baptiste Combes; validation, Anabelle 456 Wong, Annick Opinel and Simon Jean-Baptiste Combes; formal analysis, Anabelle Wong; investigation, 457 Anabelle Wong; resources, Annick Opinel, Julie Toubiana and Sylvain Brisse; data curation, Anabelle Wong; 458 writing-original draft preparation, Anabelle Wong; writing-review and editing, Annick Opinel, Simon 459 Jean-Baptiste Combes, Julie Toubiana and Sylvain Brisse; visualization, Anabelle Wong; supervision, Annick 460 Opinel and Simon Jean-Baptiste Combes; project administration, Anabelle Wong and Annick Opinel; funding 461 acquisition, Sylvain Brisse.

462 Funding: This project was funded by the INCEPTION interdisciplinary project at Institut Pasteur, 463 "Understanding whooping cough resurgence in Europe by combing genomic, epidemiological and sociological 464 approaches" (Eronch Covernment Investiggements d'Avenir grant ANR 16 CONV 0005)

464 approaches" (French Government Investissements d'Avenir grant ANR-16-CONV-0005).

Acknowledgments: The research team would like to thank Yoriko Masunaga, Institute of Tropical Medicinein
 Antwerp; Richard Cooper, University of Sheffield; Didier Guillemot, Tamara Giles-Vernick and Matthieu
 Domenech de Cellès, Institut Pasteur, for their valuable advice and resourcefulness. We would also like to
 express our heart-felt gratitude to Daniel Levy-Bruhl, Daniel Floret, Nicole Guiso, Tine Dalby, Michał

469 Zabdyr-Jamróz, Sven-Arne Silfverdal and other experts who have offered their support to this project.

470 **Conflicts of Interest**: The authors declare no conflict of interest.

				Booster	Booster
Country	Year	Vaccine	Prime schedule	(childhood)	(teenage)
Belgium	1950s	wP	3 / 4 / 5 / 13mo		
	1999	DTaP; wP in FR			
	2001	DTaP-IPV			
	2003		2 / 3 / 4 / 15mo		
	2004	DTaP-IPV-Hib/HB		4-6yr DTaP-IPV	
	2009				14-16yr dTap
			0 / 6wk / 6 /		
Czech	1958	wP	18-20mo	3 / 6 yr wP	
			9 / 13 / 17wk /		
	1991	DTwP	18-20mo	5yr DTwP	
			9 / 13 / 17wk /		
	2007	DTaP	18-20mo	5-6yr DTaP	
					10-11yr
	2009				DTaP-IPV
	2016	DTaP-IPV-Hib/HB	3 / 5 / 11-13mo		
Denmark	1961	DTwP	5 / 6 / 7 / 15mo		
	1969	wP	5wk / 9wk / 10mo		
	1997	DTaP-IPV	3 / 5 / 12mo		
	2002	DTaP-IPV/Hib			
	2003			5yr dTaP	
	2004			, 5yr dTaP-IPV	
Finland	1952	DwP	3 / 4 / 5mo	,	
			, ,	3-4 / 6-7 yr	
	1957	DTwP		DTwP	
	1977		3 / 4 / 5 / 24mo		
	2003		, , ,	6yr dtaP	
	2005	DTaP-IPV-Hib	3 / 5 / 12mo	,	
	2008			4yr DTaP-IPV	
	2009			,	11-13yr dtaP
	2011				, 14-15yr dtaP
France	1959	wP	3 / 4 / 5 / 18-24mo		,
-	1966	DTwP-IPV	3 / 4 / 5 / 18-24mo		
	1995	DTwP-IPV-Hib	2/3/4/16-18mo		
			, , ,		11-13yr
	1998				DTaP-IPV
	2004	DTaP-IPV-Hib			
		DTaP-IPV-Hib			11-13yr
	2008	(HB)			dTaP-IPV
	2000		2 / 4 / 11mo	6yr DTaP-IPV	

472 Appendix A: Pertussis Vaccination Policy in 14 EU Countries since Introduction. [3,4,6,16-50]

Germany	1964	wP in GDR			
,	1969	wP in FWG			
	1974	Nil in FWG			
	1991	DTwP in all	3/4/5/24mo		
	1995		3/4/5/13mo		
	2000		2/3/4/11-14mo		9-17yr dTaP
	2006			5-6yr dTaP	
Ireland	1952	DTwP		-	
	1995	DTwP	2 / 4 / 6mo		
	2001	DTaP-IPV-Hib			
	2008	DTaP-IPV-Hib/HB			
	2010			4-5yr DTaP	
	2012				12-13yr dTaP
	2016				
Italy	1961	wP	3 / 5 / 11-12mo		
-	1995	DTaP	3 / 5 / 11mo		
	1999			5-6yr DTaP	
	2012				11-18yr dTaP
The					
Netherlands	1957	DTwP	3 / 4 / 5mo		
	1962	DTwP-IPV	3 / 4 / 5 / 11mo		
	1993	DTwP-IPV, Hib			
	1999		2/3/4/11mo		
	2002			4yr aP	
	2003	DTwP-IPV-Hib			
	2005	DTaP-IPV-Hib	2/3/4/11mo		
	2006			4yr DTaP-IPV	
	2008				
	2010				
	2011	DTaP-IPV-Hib/HB			
	2017			4yr dTaP	
Norway	1952	DTwP	3 / 4 / 5 / 15-18mo		
	1984		3 / 5 / 10mo		
	1998	DTaP-IPV/Hib			
	2006		3 / 5 / 12mo	7yr DTaP-IPV	
	2012				15yr DTaP-IPV
Poland	1960	DTwP	2 / 3-4 / 5 / 16-18mo		
	2004			6yr DTaP	
	2016				14yr dTaP

Spain	1965	wP			
	1967				
	1975		3 / 5 / 7mo		
			2-3 / 4-5 / 6-7 /		
	1995	DTwP	18mo		
	2000		2 / 4 / 6 / 18mo	4-6yr DTaP	
	2005	DTaP			
				4-6yr	
	2012			DTaP/dTaP	11-14yr dTaP
	2014				11-12yr dTaP
	2015			6yr DTaP/dTaP	
	2016	DTaP-IPV-Hib/HB	2 / 4 / 12mo	6yr dTaP-IPV	
Sweden	1953	DTwP	3 / 5 / 12mo		
	1979	Nil			
	1996	DTaP	3 / 5 / 12mo		
	1998	DTaP-IPV/Hib	3 / 5 / 12mo		
					10yr DTaP till
	2005				2011
	2007			5-6yr DTaP-IPV	
	2016				14-16yr dTap
UK	1957	DTwP			
	1968		3 / 5 / 11mo		
	1990		2 / 3 / 4mo		
	2000	(DTaP3-Hib)			
				3yr4mo	
	2001	(DTaP3-Hib)		DTaP-IPV	
	2004	DTaP-IPV-Hib	2 / 3 / 4mo		
	2017	DTaP-IPV-Hib/HB			14yr dT-IPV

479	Re	ferences
480	1.	National Health Service. Whooping cough. Available online:
481	1.	https://www.nhs.uk/conditions/whooping-cough/ (accessed on 12 Feb 2019).
482	2.	Amirthalingam, G.; Gupta, S. and Campbell H. Pertussis immunisation and control in England and Wales,
483	4.	1957 to 2012: A historical review. Euro Surveill 2013 , 18(38), pii20587.
484	3.	Caro, V.; Njamkepo, E.; Van Amersfoorth, S.C.M.; Mooi, F.R.; Advani, A.; Hallander, H.O. et al.
485	0.	Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries
486		with different vaccine policies. <i>Microbes Infect</i> 2005 , <i>7</i> , 976-982.
487	4.	Advani, A.; Hallander, H.O.; Dalby, T.; Krogfelt, K.A.; Guiso, N.; Njamkepo, E. et al. Pulsed-field gel
488	1.	electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. <i>J Clin</i>
489		Microbiol 2013 , 51(2), 422-428.
490	5.	Barkoff, A.; Mertsola, J.; Pierard, D.; Dalby, T.; Hoegh, S.V.; Guillot, S. et al. Surveillance of circulating
491	0.	Bordetella pertussis strains in Europe during 1998 to 2015. J Clin Microbiol 2018 , 56(5), e01998-17.
492	6.	World Health Organization. SAGE pertussis working group background paper. 2014 .
493	0. 7.	Preston, A. The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible
494	7.	consequences for vaccine development. <i>Hum Vaccin Immunother</i> 2016 , 12(5), 1274–1276.
495	8.	Domenech de Celles, M.; Magpantay, F.M.G.; King, A.A. and Rohani, P. The pertussis enigma: Reconciling
496	0.	epidemiology, immunology and evolution. <i>Proc Royal Soc B</i> 2016 , 283(1822), 20152309.
497		doi: 10.1098/rspb.2015.2309
498	9.	Bart, M.J.; Harris, S.R.; Advani, A.; Arakawa, Y.; Bottero, D.; Bouchez, V. et al. Global population structure
499).	and evolution of <i>Bordetella pertussis</i> and their relationship with vaccination. <i>mBio</i> 2014 , <i>5</i> (2), e01074-14.
500		doi:10.1128/mBio.01074-14.
500	10.	
501	10.	pertussis strains circulating in Europe in 1994 to 2004 as determined by pulsed-field gel electrophoresis. J
502		Clin Microbiol 2007 , 45(10), 3257-3262.
503	11.	
505	11.	Bordetella pertussis isolates. <i>Vaccines (Basel)</i> 2015 , <i>3(3)</i> , 751–770.
505	12.	Martin, S.W.; Pawloski, L.; Williams, M.; Weening, K.; DeBolt, C.; Qin, X. et al.
507	12.	Pertactin-Negative Bordetella pertussis Strains: Evidence for a possible selective advantage. Clin Infect Dis
508		2015 , 60(2), 223–227
509	13.	Mooi, F.R.; Van der Maas, N.A.T. and De Melker, H.E. Pertussis resurgence: waning immunity and
510	10.	pathogen adaptation – two sides of the same coin. <i>Epidemiol Infect</i> 2014 , 142, 685–694
511	14.	Bodilis, H. and Guiso, N. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France.
512	1 1.	<i>Emerg Infect Dis</i> 2013 , 19(3), 471-474. doi: 10.3201/1903.121475.
512	15.	Clarke, M.; McIntyre, P.B., Blyth, C.C.; Wood, N.; Octavia, S.; Sintchenko, V. et al. The relationship
514	10.	between Bordetella pertussis genotype and clinical severity in Australian children with pertussis. J Infect
515		2016 , 72(2), 171-178.
516	16.	European Centre for Disease Prevention and Control. Vaccine schedules in all countries of the European
517	10.	Union. Available online: https://vaccine-schedule.ecdc.europa.eu/ (accessed on 14 Feb 2019).
518	17.	Therre, H. and Baron, S. Pertussis immunization in Europe – the situation in late 1999. Euro Surveill 2000 ,
519		5(1), 6-10.
520	18.	Van Kerschaver, E. The Belgian expanded Programme on immunization (EPI) and hepatitis B vaccination.
521		S Afr J Epidemiol Infect 2008, 23(1), 40-44.
522	19.	Maertens, K.; Cabore, R.N.; Huygen, K.; Hens, N.; Van Damme, P. and Leuridan, E. Pertussis vaccination
523		during pregnancy in Belgium: Results of a prospective controlled cohort study. Vaccine 2016, 34 (1),
524		142-150.
525	20.	Maertens, K.; Braeckman, T.; Top, G.; Van Damme, P. and Leuridan, E. Maternal pertussis and influenza
526		immunization coverage and attitude of health care workers towards these recommendations in Flanders,
527		Belgium. Vaccine 2016 , 34 (1), 5785-5791.
528	21.	-
529		https://www.vaccination-info.be/maladie/coqueluche/ (accessed on19 Feb 2019). (French)
530	22.	The Citizens Information Portal of the German-speaking Community of Belgium. [The optimal
531		vaccination schedule]. Available online:
		-

532		https://translate.google.fr/?hl=en&tab=rT&authuser=0#view=home&op=translate&sl=de&tl=en&text=Das
533	• •	%20optimale%20Impfschema (accessed on 19 Feb 2019). (German)
534	23.	Flanders Care and Health. [Basic vaccination schedule]. Available online:
535	. .	https://www.zorg-en-gezondheid.be/basisvaccinatieschema (accessed on 19 Feb 2019). (Dutch)
536	24.	Heininger, U.; Andre, P.; Chlibek, R.; Kristufkova, Z.; Kutsar, K.; Manarov, A. et al. Comparative
537		epidemiologic characteristics of pertussis in 10 Central and Eastern European countries, 2000-2013. PLoS
538		ONE 2016, 11(6), e0155949. doi:10.1371/journal.pone.0155949
539	25.	Chlibek, R.; Smetana, J.; Sosovickova, R.; Fabianova, K.; Zavadilova, J.; Dite, P. et al. Seroepidemiology of
540		whooping cough in the Czech Republic: estimates of incidence of infection in adults. <i>Public Health</i> 2017 ,
541 542	•	150, 77-83.
542	26.	National Immunisation Committee of Czech Republic. Recommendation for pertussis vaccination in
543		pregnancy for the Czech Republic. 2015 Dec 8. Available online:
544 545		http://www.szu.cz/uploads/Epidemiologie/Pertuse/CR_Pertussis_Recommendation_for_pregnant_wome
545		n.pdf (accessed on 14 Feb 2019).
546	27.	
547	• •	Surveill 2016 , 21(36), pii=30334. doi: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.36.30334
548	28.	Zoeldi, V.; Sane, J.; Nohynek, H.; Virkki, M.; Hannila-Handelberg, T. and Mertsola, J. Decreased incidence
549		of pertussis in young adults after the introduction of booster vaccine in military conscripts:
550	• •	Epidemiological analyzes of pertussis in Finland, 1995-2015. <i>Vaccine</i> 2017 , <i>35</i> , 5249-5255.
551	29.	
552		2013 Jun 12-14, Clermont-Ferrand. (French)
553	30.	National Institute of Prevention and Health Education (INPES). [The vaccination against whooping
554	24	cough]. 1999. (French)
555	31.	National Institute of Prevention and Health Education (INPES). [The vaccination Guide]. 2012. (French)
556	32.	High Council of Public Health (HCSP). [Vaccine schedule and vaccination recommendations]. 2015.
557		(French)
558	33.	National Institute of Prevention and Health Education (INPES). [The vaccination against whooping
559		cough], 2016. Available online:
560		https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/documents/depliant-flyer/la-vacc
561		ination-contre-la-coqueluche-rpvp-mars-2016(accessed on 14 Feb 2019). (French)
562	34.	Hellenbrand, W.; Beier, D.; Jensen, E.; Littmann, M.; Meyer, C.; Oppermann, H. et al. The epidemiology of
563		pertussis in Germany: past and present. <i>BMC Infect Dis</i> 2009 , <i>9</i> , 22-33.
564	35.	Robert Koch Institute. [Epidemiology Bulletin]. 2000 Jan 14. (German)
565	36. 2 7	Robert Koch Institute. [Epidemiology Bulletin]. 2001 Jan 13. (German)
566	37.	Robert Koch Institute. [Epidemiology Bulletin]. 2006 Jul 28. (German)
567	38.	Cocoran, B. National Immunisation Study Day. The national immunisation schedule update and current
568		issues. Dublin: 2014 Sep 12. Available online:
569 570		https://www.hse.ie/eng/health/immunisation/hcpinfo/conference/conference120914.html (accessed on 19
570 571	20	Feb 2019).
572	39.	Health Service Executive National Immunisation Office. Immunisation schedule. Available online:
572		https://www.hse.ie/eng/health/immunisation/pubinfo/pcischedule/immschedule/ (access on 10 Feb
575 574	40	2019). Configuratini M.V. Carloni F. Convoldo F. Bandolfi F. Apricolo F. Dimeuto F. et al. Enidomiology of
575	40.	
576	41.	pertussis in Italy: Disease trends over the last century. <i>Euro Surveill</i> 2014 , <i>19</i> (40), pii=20921. The Italian Vaccine Coverage Survey Working Group. Childhood vaccination coverage in Italy: Results of
577	41.	a seven-region survey. Bull of the World Health Organ 1994 , 72(6), 885-895.
578	42.	Bonanni P., Ferro A., Guerra R. Iannazzo S., Odone A., Pompa M.G. et al. Vaccine coverage in Italy and
570 579	74.	assessment of the 2012-2014 National Immunization Prevention Plan. Epidemiologia & Prevenzione 2015,
580		39(4) Suppl 1, 145-158.
581	43.	The National Institute for Public Health and the Environment (RIVM). Adverse events in the Netherlands
582	10.	vaccination programme. 2011.
583	44.	Lavine, J.; Bjørnstada, O.N.; de Blasio, B. F. and Storsæter, J. Short-lived immunity against pertussis,
584		age-specific routes of transmission, and the utility of a teenage booster vaccine. <i>Vaccine</i> 2011 , <i>30</i> (3),
585		544–551. doi:10.1016/j.vaccine.2011.11.065

586	45.	Bednarek, A.; Bodajko-Grochowska, A.; Hasiec, B.; Klepacz, R.; Szczekala, K.; Zarzycka, D. et al. In search
587		of factors negatively affecting vaccine immunity to pertussis in preschool children before the
588		administration of the first booster. Int J Environ Res Public Health 2018, 15, 1432-1446.
589	46.	National Institute of Public Health- National Institute of Hygiene (NIPH-NIH). Immunization schedule.
590		Available online: http://szczepienia.pzh.gov.pl/en/immunization-schedule/ (accessed on 14 Feb 2019).
591	47.	Latasa, P.; Garcia-Comas, L.; Gil de Miguel, A.; Barranco, M.D.; Rodero, I.; Sanz, J.C. et al. Effectiveness of
592		acellular pertussis vaccine and evolution of pertussis incidence in the community of Madrid from 1998 to
593		2015. Vaccine 2018 , 36, 1643-1649.
594	48.	Working Group of Whooping Cough, Ministry of Health, Social Service and Equality. [Review of the
595	10.	program of vaccination against whooping cough in Spain]. 2012. (Spanish)
596	49.	Hallander, H. and Gustafsson, L. Efficiacy and effectiveness of acellular pertussis vaccines: A 20-year
597	ч <i>у</i> .	Swedish experience. <i>Expert Rev of Vaccines</i> 2009 , <i>8</i> (10), 1303-1307.
598	50.	Aronsson, B.; Källberg, H.; Byström, E. and Drakes-Jämtberg, K. Pertussis surveillance in Sweden:
599	50.	Progress report October1997-December 2018 with an executive summary. The Public Health Agency of
600		Sweden; 2017. Available online: https://www.folkhalsomyndigheten.se (accessed on 14 Feb 2019).
601	E1	
602	51.	Thierry-Carstensen, B.; Dalby, T.; Stevner, M.A.; Robbins, J.B.; Schneerson, R. and Trollfors, B. Experience
602 603		with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and
603 604		adults – a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field
	-0	experience. Vaccine 2013 , 31, 5178-5191.
605	52.	Mueller, J.; Koutangni, T.; Diallo, C. and Yaro, S. Comparative efficacy / effectiveness of schedules in infant
606		immunization against pertussis, diphtheria and tetanus: Systematic review and meta-analysis. Part 2:
607		Whole-cell pertussis vaccine. World Health Organization (Report Draft) 2014 Aug 13.
608	53.	Olin, P.; Hallander, H.O.; Gustafsson, L.; Barreto, L. and Podda, A. Measuring protection; a case study of
609		pertussis vaccines – Swedish Trial II: secondary non-randomized comparisons between two schedules of
610		infant vaccination. <i>Dev Biol Stand</i> 1998 , 95, 211-20.
611	54.	Miller, E.; Ashworth, M.A.E.; Redhead, K.; Thornton, C.; Waight, P.A.; Coleman, T. Effect of schedule on
612		reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory
613		tests as predictors of clinical performance. Vaccine 1997 , 15, 51-60.
614	55.	DiCicco-Bloom, B. and Crabtree, B.F. The qualitative research interview. <i>Med Educ</i> 2006 , <i>40</i> , 314-321.
615	56.	Given, L.M. The SAGE encyclopedia of qualitative research methods; SAGE: Los Angeles, US, 2008; pp. 810-811.
616	57.	Boyce, C. and Neale, P. Conducting in-depth interview: A guide for designing and conducting in-depth interviews
617		for evaluation input. Pathfinder International: Watertown, US, 2006; pp. 11-12.
618	58.	Holton, J.A. The coding process and its challenges. Grounded Theory Review 2010, 9 (1), 21-40.
619	59.	Campbell, J.L.; Quincy, C.; Osserman, J. and Pedersen, O.K. Coding in-depth semistructured interviews :
620		problems of unitization and intercoder reliability and agreement. Sociol Methods Res 2013, 42(3), 294-320.
621	60.	Krippendorff, K. Content Analysis: An introduction to its methodology, 2nd ed.; SAGE: London, UK, 2004; pp.
622		221-251.
623	61.	Landis, J.R. and Kock, G.G. The measurement of observer agreement for categorical data. Biometrics 1977;
624		33, 159-174.
625	62.	World Health Organization. Immunization, vaccines and biologicals: pertussis. Available online:
626		https://www.who.int/immunization/diseases/pertussis/en/ (accessed on 27 May 2019).
627	63.	Silva, M.L.; Perrier, L.; Paget, J.W.; Mosnier, A.; Buthion, V.; Cohen, J.M. et al. Influenza vaccination
628		policy-making process in France and the Netherlands: framework and determinants. Health Policy 2016,
629		120, 293-305.
630	64.	Public Health England. Laboratory confirmed cases of pertussis (England): January to March 2019.
631		Available online:
632		https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/81329
633		2/hpr2219_prtsss.pdf (accessed on 07 Jul 2019).
634	65.	High Authority of Health (HAS). [The vaccination against whooping cough for pregnant women in the
635		context of epidemic in Mayotte]. 2018. (French)
636	66.	High Authority of Health (HAS). [The vaccination against whooping cough for pregnant women]. 2019.
637		Available online:
638		https://www.has-sante.fr/upload/docs/application/pdf/2019-07/recommandation_vaccinale_contre_la_coq
639		ueluche_chez_la_femme_enceinte_feuille_de_route.pdf (accessed on 15 Aug 2019). (French)

- 640 67. Kvale S. Ten standard objections to qualitative research interviews. *J Phenomenol Psychol* 1994, 25(2), 147-173.
- 642 68. Seale C. and Silverman D. Ensuring rigour in qualitative research. *Eur J Public Health* **1997**, *7*, 379-384.
- 643 69. Bonde D. *Qualitative interview: when enough is enough*. Research by Design: Australia, 2013.
- 644 70. Geyer R. and Rihani S. Complexity and public policy: a new approach to 21st century politics, policy, and society,
 645 1st ed.; Routledge: New York, 2010.



© 2019 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).